Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia.
about
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparinA phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.Management of heparin-induced thrombocytopenia.Inhibition of Plasmodium falciparum growth in vitro and adhesion to chondroitin-4-sulfate by the heparan sulfate mimetic PI-88 and other sulfated oligosaccharides.Overview of the clinical efficacy of investigational anticancer drugs.An experimental and molecular-modeling study of the binding of linked sulfated tetracyclitols to FGF-1 and FGF-2.
P2860
Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Treatment with the novel anti- ...... une-mediated thrombocytopenia.
@ast
Treatment with the novel anti- ...... une-mediated thrombocytopenia.
@en
type
label
Treatment with the novel anti- ...... une-mediated thrombocytopenia.
@ast
Treatment with the novel anti- ...... une-mediated thrombocytopenia.
@en
prefLabel
Treatment with the novel anti- ...... une-mediated thrombocytopenia.
@ast
Treatment with the novel anti- ...... une-mediated thrombocytopenia.
@en
P2093
P356
P1433
P1476
Treatment with the novel anti- ...... une-mediated thrombocytopenia.
@en
P2093
G McArthur
M A Rosenthal
R L Basser
P304
P356
10.1093/ANNONC/MDF117
P50
P577
2002-05-01T00:00:00Z